Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2012; 11(03): 105-109
DOI: 10.4103/1450-1147.103408
Original Article

Standard Operating Procedure for In-house Preparation of 131 I-rituximab for Radioimmunotherapy of Non-Hodgkin′s Lymphoma

Matthew Pickford
Department of Nuclear Medicine, The University of Western Australia, Fremantle Hospital, Fremantle WA, Australia
,
J. Turner
Department of Nuclear Medicine, The University of Western Australia, Fremantle Hospital, Fremantle WA, Australia
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

A Standard Operating Procedure (SOP) has been formulated for in-house preparation, quality control, dispensing and administration of 131 I-rituximab appropriate for the safe, effective, radioimmunotherapy of non-Hodgkin lymphoma. A decade of experience of semi-automated radioiodination of rituximab in our hospital radiopharmaceutical laboratory was analysed. The methodology was then refined for safe, practical, affordable application to radioimmunotherapy of lymphoma in departments of nuclear medicine in developing countries. This SOP has the potential to be incorporated into good laboratory practice conditions appropriate for local regulatory agency requirements.

Keywords

Iodine-131 - standard operating procedures - radioimmunotherapy


Publication History

Article published online:
21 May 2022

© 2012. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India